Corrections:

Hongyan Yuan¹, Xiaoyi Wang¹, Jin Lu¹, Qiongsi Zhang¹, Irina Brandina², Ilya Alexandrov² and Robert I. Glazer¹

¹ Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
² ActivSignal, LLC, Natick, MA 01760, USA

Published: December 28, 2018

This article has been corrected: This article has been corrected: Due to a labeling error, the legends for Figures 2 and 3 were accidentally switched. The proper figure legends are given below. The authors declare that these corrections do not change the results or conclusions of this paper.

Figure 2: Induction of fibrosis in the mammary gland of NeuT/ATTAC mice following AP21087 treatment for four weeks. Six-week-old NeuT/ATTAC mice were injected i.p. with vehicle (NeuT/ATTAC) or 0.4 mg/kg AP21087 (NeuT/ATTAC+AP) for four weeks. FFPE sections were stained as described in Figure 2. Magnification 400×.

Figure 3: Induction of fibrosis in NeuT/ATTAC mice. Mice at 6 weeks-of-age were injected i.p. with vehicle (NeuT/ATTAC) three times weekly for 5.5 months (NeuT/ATTAC) or with 0.4 mg/kg AP21087 (NeuT/ATTAC+AP) for 4 months. FFPE sections were stained with H&E, for collagen (PicroSirius Red) and with antibodies against Ki-67, CD31, α-smooth muscle actin (SMA), F4/80, Cxcl1, Foxp3, CD8 and PD-L1. Magnification 400×.

Original article: Oncotarget. 2018; 9:8042-8053. DOI: https://doi.org/10.18632/oncotarget.24233.